Between February 1981 and December 1984 we treated 52 patients with chronic myeloid leukemia in the chronic phase and 18 patients with more advanced disease by high-dose chemoradiotherapy followed by allogeneic bone marrow transplantation using marrow cells from HLA-identical sibling donors. In addition, the 40 patients who had not previously undergone splenectomy received radiotherapy to the spleen. To prevent graft versus host disease, cyclosporine was given either alone or in conjunction with donor marrow depleted of T cells. Of the 52 patients treated in the chronic phase, 38 are alive after a median follow-up of 25 months (range, 7 to 50); the actuarial survival at two years was 72 percent, and the actuarial risk of relapse was 7 percent. Of the 18 patients with more advanced disease, 4 have survived; the actuarial two-year survival was 18 percent, and the actuarial risk of relapse was 42 percent. We conclude that the probability of cure is highest if transplantation is performed while the patient remains in the chronic phase of chronic myeloid leukemia. T-cell depletion may have reduced the incidence and severity of graft versus host disease. The value of irradiation to the spleen before transplantation has not been established.
This article has been cited by other articles:
Yong, A. S. M., Rezvani, K., Savani, B. N., Eniafe, R., Mielke, S., Goldman, J. M., Barrett, A. J.
(2007). High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood
110: 770-775
[Abstract][Full Text]
Kaeda, J., O'Shea, D., Szydlo, R. M., Olavarria, E., Dazzi, F., Marin, D., Saunders, S., Khorashad, J. S., Cross, N. C. P., Goldman, J. M., Apperley, J. F.
(2006). Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood
107: 4171-4176
[Abstract][Full Text]
Cwynarski, K., Roberts, I. A. G., Iacobelli, S., van Biezen, A., Brand, R., Devergie, A., Vossen, J. M., Aljurf, M., Arcese, W., Locatelli, F., Dini, G., Niethammer, D., Niederwieser, D., Apperley, J. F.
(2003). Stem cell transplantation for chronic myeloid leukemia in children. Blood
102: 1224-1231
[Abstract][Full Text]
Or, R., Shapira, M. Y., Resnick, I., Amar, A., Ackerstein, A., Samuel, S., Aker, M., Naparstek, E., Nagler, A., Slavin, S.
(2003). Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood
101: 441-445
[Abstract][Full Text]
Weisdorf, D. J., Anasetti, C., Antin, J. H., Kernan, N. A., Kollman, C., Snyder, D., Petersdorf, E., Nelson, G., McGlave, P.
(2002). Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood
99: 1971-1977
[Abstract][Full Text]
Petersdorf, E. W., Kollman, C., Hurley, C. K., Dupont, B., Nademanee, A., Begovich, A. B., Weisdorf, D., McGlave, P.
(2001). Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood
98: 2922-2929
[Abstract][Full Text]
Michallet, M., Bilger, K., Garban, F., Attal, M., Huyn, A., Blaise, D., Milpied, N., Moreau, P., Bordigoni, P., Kuentz, M., Sadoun, A., Cahn, J.-Y., Socie, G., Thomas, X., Arnaud, P., Raus, N., Lheritier, V., Pigneux, A., Boiron, J.-M.
(2001). Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome. JCO
19: 3340-3349
[Abstract][Full Text]
Dazzi, F., Szydlo, R. M., Cross, N. C. P., Craddock, C., Kaeda, J., Kanfer, E., Cwynarski, K., Olavarria, E., Yong, A., Apperley, J. F., Goldman, J. M.
(2000). Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood
96: 2712-2716
[Abstract][Full Text]
Verfuerth, S., Peggs, K., Vyas, P., Barnett, L., O'Reilly, R. J., Mackinnon, S.
(2000). Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood
95: 3990-3995
[Abstract][Full Text]
McGlave, P. B., Shu, X. O., Wen, W., Anasetti, C., Nademanee, A., Champlin, R., Antin, J. H., Kernan, N. A., King, R., Weisdorf, D. J.
(2000). Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood
95: 2219-2225
[Abstract][Full Text]
Giralt, S., Szydlo, R., Goldman, J. M., Veum-Stone, J., Biggs, J. C., Herzig, R. H., Klein, J. P., McGlave, P. B., Schiller, G., Gale, R. P., Rowlings, P. A., Horowitz, M. M.
(2000). Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the International Bone Marrow Transplant Registry. Blood
95: 410-415
[Abstract][Full Text]
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., Talpaz, M., Tura, S.
(1999). An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, Interferon, and Allogeneic Bone Marrow Transplantation in Treating the Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Society of Hematology. Blood
94: 1517-1536
[Abstract][Full Text]
Carella, A. M., Lerma, E., Corsetti, M. T., Dejana, A., Basta, P., Vassallo, F., Abate, M., Soracco, M., Benvenuto, F., Figari, O., Podesta, M., Piaggio, G., Ferrara, R., Sessarego, M., Parodi, C., Pizzuti, M., Rubagotti, A., Occhini, D., Frassoni, F.
(1999). Autografting With Philadelphia Chromosome-Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia. Blood
93: 1534-1539
[Abstract][Full Text]
Sausville, E. A.
(1999). A Bcr/Abl Kinase Antagonist for Chronic Myelogenous Leukemia: a Promising Path for Progress Emerges. JNCI J Natl Cancer Inst
91: 102-103
[Full Text]
Petersdorf, E. W., Gooley, T. A., Anasetti, C., Martin, P. J., Smith, A. G., Mickelson, E. M., Woolfrey, A. E., Hansen, J. A.
(1998). Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. Blood
92: 3515-3520
[Abstract][Full Text]
Hansen, J. A., Gooley, T. A., Martin, P. J., Appelbaum, F., Chauncey, T. R., Clift, R. A., Petersdorf, E. W., Radich, J., Sanders, J. E., Storb, R. F., Sullivan, K. M., Anasetti, C.
(1998). Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia. NEJM
338: 962-968
[Abstract][Full Text]
Slattery, J.T., Clift, R.A., Buckner, C.D., Radich, J., Storer, B., Bensinger, W.I., Soll, E., Anasetti, C., Bowden, R., Bryant, E., Chauncey, T., Deeg, H.J., Doney, K.C., Flowers, M., Gooley, T., Hansen, J.A., Martin, P.J., McDonald, G.B., Nash, R., Petersdorf, E.W., Sanders, J.E., Schoch, G., Stewart, P., Storb, R., Sullivan, K.M., Thomas, E.D., Witherspoon, R.P., Appelbaum, F.R.
(1997). Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation. Blood
89: 3055-3060
[Abstract][Full Text]
Petersdorf, E. W., Longton, G. M., Anasetti, C., Mickelson, E. M., McKinney, S. K., Smith, A. G., Martin, P. J., Hansen, J. A.
(1997). Association of HLA-C Disparity With Graft Failure After Marrow Transplantation From Unrelated Donors. Blood
89: 1818-1823
[Abstract][Full Text]
Armitage, J. O.
(1994). Bone Marrow Transplantation. NEJM
330: 827-838
[Full Text]
Shannon, K. M., Cowan, M. J., Matthay, K. K.
(1987). Pediatric Bone Marrow Transplantation: Intensive Care Management. J Intensive Care Med
2: 328-344
[Abstract]
Previous
